Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr:7:530-537.
doi: 10.1200/GO.20.00421.

Treatment of Localized and Locally Advanced, High-Risk Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries

Raja Khauli  1 , Robson Ferrigno  2 , Gustavo Guimarães  2 , Muhammad Bulbulan  3 , Pedro Luiz Serrano Uson Junior  4 , Bernardo Salvajoli  5   6 , Daniel Moore Freitas Palhares  7 , Douglas Racy  2 , Erlon Gil  2 , Fernando Freire de Arruda  7 , Gustavo Caserta Lemos  4 , Gustavo Franco Carvalhal  8 , Icaro Thiago de Carvalho  4 , Igor Austin Fernandes Martins  2 , Ivan Frederico Pinto Gimpel  9 , João Victor Salvajoli  5   6 , José Luis Chambo  2 , José Pontes Jr  5 , Leopoldo Alves Ribeiro Filho  7 , Lucas Nogueira  10 , Marcelo Roberto Pereira Freitas  11 , Marcelo Wroclawski  4 , Marco Antonio Arap  7 , Marcus Vinicius Sadi  2 , Rafael Coelho  5 , Rafael Gadia  7 , Rodrigo Antonio Ledezma Roja  12 , Rodrigo de Moraes Hanriot  13 , Ronaldo Baroni  4 , Stenio Zequi  14 , William Carlos Nahas  5 , Wladimir Alfer Jr  4 , Fernando Cotait Maluf  2   4   15
Affiliations

Treatment of Localized and Locally Advanced, High-Risk Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries

Raja Khauli et al. JCO Glob Oncol. 2021 Apr.

Abstract

Purpose: To generate and present survey results on important issues relevant to treatment and follow-up of localized and locally advanced, high-risk prostate cancer (PCa) focusing on developing countries.

Methods: A panel of 99 PCa experts developed more than 300 survey questions of which 67 questions concern the main areas of interest of this article: treatment and follow-up of localized and locally advanced, high-risk PCa in developing countries. A larger panel of 99 international multidisciplinary cancer experts voted on these questions to create the recommendations for treatment and follow-up of localized and locally advanced, high-risk PCa in areas of limited resources discussed in this article.

Results: The panel voted publicly but anonymously on the predefined questions. Each question was deemed consensus if 75% or more of the full panel had selected a particular answer. These answers are based on panelist opinion and not on a literature review or meta-analysis. For questions that refer to an area of limited resources, the recommendations considered cost-effectiveness as well as the possible therapies with easier and greater access. Each question had five to seven relevant answers including two nonanswers. Results were tabulated in real time.

Conclusion: The voting results and recommendations presented in this article can guide physicians managing localized and locally advanced, high-risk PCa in areas of limited resources. Individual clinical decision making should be supported by available data; however, as guidelines for treatment of localized and locally advanced, high-risk PCa in developing countries have not been defined, this article will serve as a point of reference when confronted with this disease.

PubMed Disclaimer

Conflict of interest statement

Raja KhauliHonoraria: Astellas Pharma, Janssen, Algorithm, Hikma, LillyConsulting or Advisory Role: Astellas Pharma, HikmaSpeakers' Bureau: Algorithm, LillyResearch Funding: Astellas Pharma Leopoldo Alves Ribeiro FilhoConsulting or Advisory Role: FerringSpeakers' Bureau: Zodiac Pharma Lucas NogueiraConsulting or Advisory Role: BayerSpeakers' Bureau: Bayer, Astellas Pharma Marcelo Roberto Pereira FreitasConsulting or Advisory Role: Janssen Oncology, Zodiac PharmaSpeakers' Bureau: Astellas Pharma, Janssen Oncology Rodrigo Antonio Ledezma RojaHonoraria: Ferring, Quanta SystemsConsulting or Advisory Role: Quanta Systems, FerringTravel, Accommodations, Expenses: Quanta Systems Rodrigo de Moraes HanriotSpeakers' Bureau: AstraZeneca, Varian Medical Systems, Bristol Myers Squibb, Takeda, Roche Stenio ZequiConsulting or Advisory Role: Pfizer, Astellas BrazilSpeakers' Bureau: Pfizer, Astellas Pharma, Bayer, Janssen, Astra Zeneca Brazil Fernando Cotait MalufHonoraria: Janssen Oncology, Astellas Pharma, Bayer Schering Pharma, Merck Sharp & Dohme, Roche/Genentech, BMS Brazil, Ipsen, Sanofi/Aventis, Merck Serono, AstraZenecaConsulting or Advisory Role: Janssen Oncology, Astellas Pharma, Bayer Schering Pharma, Merck Sharp & Dohme, Roche/Genentech, BMS Brazil, Ipsen, Merck Serono, AstraZenecaResearch Funding: Janssen-Cilag, Merck Sharp & DohmeTravel, Accommodations, Expenses: Merck Sharp & Dohme, Bayer Schering PharmaNo other potential conflicts of interest were reported.

Similar articles

  • Consensus on Prostate Cancer Treatment of Localized Disease With Very Low, Low, and Intermediate Risk: A Report From the First Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).
    Luz MA, Guimarães GC, Nardi AC, Pompeo ASFL, Sarkis ÁS, Nowier A, Lima Pompeo AC, Nardozza A Jr, Adamy A Jr, Carneiro A, Salvajoli BP, Benigno BS, Freitas CH Jr, Chade CADC, Palhares DMF, Otero DAC, Neto DCVDS, Carvalhal EF, Gil E, Freire de Arruda F, Korkes F, Caserta Lemos G, Carvalhal GF, de Carvalho ÍT, Gimpel IFP, Chambô JL, Pontes J Jr, Filho LAR, Nogueira LM, Wroclawski ML, Freitas MRP, Arap MA, Sadi MV, Bulbul M, Coelho RF, Gadia R, Khauli RB, Dos Reis RB, Rojas RAL, Guimarães RG, Aldousari S, Ferrigno R. Luz MA, et al. JCO Glob Oncol. 2021 Apr;7:523-529. doi: 10.1200/GO.20.00515. JCO Glob Oncol. 2021. PMID: 33856894 Free PMC article.
  • Consensus on Screening, Diagnosis, and Staging Tools for Prostate Cancer in Developing Countries: A Report From the First Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).
    Carneiro A, Racy D, Bacchi CE, Leite KRM, Filippi RZ, Martins IAF, Salvajoli JV, Hanriot RM, Baroni RH, Sarkis AS, Pompeo ACL, Benigno BS, Guimarães GC, Aldousari S, Nardi AC, Pompeo ASFL, Nowier A, Nardozza A Jr, Adamy A Jr, Freitas CH Jr, Chade DC, Otero DAC, Neto DCVDS, Carvalhal EF, Korkes F, Ferrigno R. Carneiro A, et al. JCO Glob Oncol. 2021 Apr;7:516-522. doi: 10.1200/GO.20.00527. JCO Glob Oncol. 2021. PMID: 33856895 Free PMC article.
  • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
    Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Gillessen S, et al. Eur Urol. 2018 Feb;73(2):178-211. doi: 10.1016/j.eururo.2017.06.002. Epub 2017 Jun 24. Eur Urol. 2018. PMID: 28655541
  • Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
    Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, … See abstract for full author list ➔ Gillessen S, et al. Eur J Cancer. 2023 May;185:178-215. doi: 10.1016/j.ejca.2023.02.018. Epub 2023 Mar 3. Eur J Cancer. 2023. PMID: 37003085
  • Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
    Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y… See abstract for full author list ➔ Gillessen S, et al. Eur Urol. 2023 Mar;83(3):267-293. doi: 10.1016/j.eururo.2022.11.002. Epub 2022 Dec 6. Eur Urol. 2023. PMID: 36494221 Free PMC article.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chang A, Autio K, Roach M, et al. “High-risk” prostate cancer: Classification and therapy Nat Rev Clin Oncol 11308–3232014 - PMC - PubMed
    1. Gay HA, Michalski JM.Radiation therapy for prostate cancer Mo Med 115146–1502018 - PMC - PubMed
    1. Worthington JF. Treatment for prostate cancer: External-beam radiation therapy. https://www.pcf.org/c/treatment-for-prostate-cancer-external-beam-radiat...
    1. Fischer-Valuck BW, Rao YJ, Michalski JM, et al. Intensity-modulated radiotherapy for prostate cancer Transl Androl Urol 7297–3072018 - PMC - PubMed
    1. Konski A.Cost effectiveness of prostate cancer radiotherapy Transl Androl Urol 7371–3772018 - PMC - PubMed